1642288-47-8 Usage
Description
Mavacamten（MYK-461）is a first-in-class allosteric inhibitor of cardiac myosin that promises to provide clinicians with targeted therapy for these patients. It is a mechanistically novel small molecule that acts on the sarcolemma to specifically inhibit contractility and has been proposed as a treatment for HCM.
Uses
MYK-461 is a drug used to treat obstructive hypertrophic cardiomyopathy as a cardiac myosin inhibitor.?Mavacamten is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy. It is used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Mechanism of action
Mavacamten is thought to work by reducing cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance. In clinical and preclinical studies, it has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility, and increased diastolic compliance.
Side effects
Common side effects include:Dizziness, fainting, Incidence not known, Chest pain or tightness, decreased urine output, dilated neck veins, irregular breathing, irregular heartbeat, swelling of the face, fingers, feet, or lower legs, trouble breathing, unusual tiredness or weakness and weight gain.
Check Digit Verification of cas no
The CAS Registry Mumber 1642288-47-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,4,2,2,8 and 8 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1642288-47:
(9*1)+(8*6)+(7*4)+(6*2)+(5*2)+(4*8)+(3*8)+(2*4)+(1*7)=178
178 % 10 = 8
So 1642288-47-8 is a valid CAS Registry Number.
1642288-47-8Relevant articles and documents
METHODS OF TREATMENT WITH MYOSIN MODULATOR
-
Paragraph 570, (2021/05/15)
Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in clinical trials with mavacamten and with mavacamten and other myosin inhibitors in the pre-clinical setting, new insights into how myosin inhibitors can be used beneficially to impact the disease state of HCM and other diseases are provided herein.
PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
-
, (2015/01/07)
Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
